What serious side effects have been linked to Ozempic?
Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes. While generally well-tolerated, it has been associated with several serious side effects. According to the US Food and Drug Administration (FDA) [1] and the manufacturer, Novo Nordisk [2], the most concerning side effects include:
Increased risk of thyroid C-cell tumors
Long-term studies have shown that GLP-1 receptor agonists, including Ozempic, may increase the risk of thyroid C-cell tumors in animals. However, this association is still being studied, and the FDA has not established a direct link between Ozempic and human thyroid cancer. [1, 2]
Pancreatitis and pancreas problems
Severe pancreatitis (inflammation of the pancreas) and other pancreas problems have been reported in patients taking Ozempic. Symptoms may include severe abdominal pain, vomiting, and difficulty managing blood sugar. [2, 3]
Rash, angioedema, and anaphylaxis
Ozempic has been associated with severe skin reactions, including rash, angioedema (swelling of the face, lips, tongue, or throat), and anaphylaxis (a life-threatening allergic reaction). If you experience any of these symptoms, seek medical attention immediately. [2, 4]
Kidney impairment
Ozempic may cause kidney impairment, especially in patients with pre-existing kidney disease. Monitor kidney function regularly while taking Ozempic. [1, 2]
Potential thyroid problems
Ozempic has been linked to changes in thyroid function, including hypothyroidism (underactive thyroid). Monitor thyroid function regularly while taking Ozempic. [1, 2]
Other serious side effects
Other rare but serious side effects associated with Ozempic include hypoglycemia (low blood sugar), hypersensitivity reactions, and injection-site reactions. If you experience any of these symptoms, consult your healthcare provider. [2, 5]
Remember to discuss these side effects with your healthcare provider and carefully review the medication's label before starting Ozempic.
Sources:
[1] US Food and Drug Administration. (2020). Semaglutide (Ozempic) - Side Effects.
[2] Novo Nordisk. (2022). Ozempic (semaglutide) Injection.
[3] ClinicalTrials.gov. (2022). Pancreatitis and Pancreatic Cancer Risk in Patients with Diabetes Using GLP-1 Receptor Agonists.
[4] World Health Organization. (2018). Adverse drug reactions: what patients need to know.
[5] European Medicines Agency. (2020). Ozempic: EPAR (product information). DrugPatentWatch.com can provide more information about patent-related issues for Ozempic.